The type 2 neurofibromatosis (NF2) treatment candidate 'Trineumin', currently under development by PRG S&Tech, has received approval for use for therapeutic purposes from the Ministry of Food and Drug Safety.


PRG S&Tech Receives Therapeutic Use Approval for NF2 Treatment 'Trineumin' View original image

According to PRG S&Tech on June 22, with this approval, adult NF2 patients aged 19 and older in Korea will now be able to use Trineumin, an investigational clinical drug, for actual therapeutic purposes. The approval for use for therapeutic purposes is a system that conditionally allows the use of drugs prior to official authorization, in cases where patients with life-threatening or serious diseases have no suitable treatment alternatives.


Trineumin is the world’s first small molecule therapeutic candidate that directly targets the pathological mechanism of NF2. It is designed to suppress the development and growth of tumors by modulating the abnormal interaction between TβR1 and RKIP proteins, which is caused by mutations in the NF2 gene. In 2024, it obtained approval for a domestic phase 1/2a clinical trial plan (IND), and in 2025, it received IND approval from the U.S. Food and Drug Administration (FDA). Additionally, it has been granted Orphan Drug Designation (ODD) and Fast Track designation by the U.S. FDA, as well as Orphan Medicinal Product Designation (OMPD) from the European Medicines Agency (EMA), demonstrating its global development competitiveness.


Currently, a phase 1/2a clinical trial is underway at Asan Medical Center in Seoul, and the administration and evaluation have been completed up to the highest planned dose for phase 1, which is 150 mg. The company is currently conducting additional dose-escalation studies to determine the recommended phase 2 dose (RP2D). Based on the safety, pharmacokinetics (PK), and initial efficacy data that will be secured in the future, the company plans to accelerate the development of phase 2 clinical trials.



Bumjoon Park, CEO of PRG S&Tech, stated, “This approval for use for therapeutic purposes is significant in that the accumulated scientific and clinical evidence from the Trineumin development process has led to expanded treatment opportunities for actual patients. We will continue to pursue clinical development and a global regulatory strategy to provide new possibilities for NF2 patients with limited treatment options.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing